Visipaque 270

   
Google
 
Web NewDrugInformation.com

Visipaque 270


Drug - Visipaque 270
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Iodixanol
Multiple ingredients are in alphabetical order.

Strength - 55%
The potency of the active ingredient(s), Iodixanol. May repeat for multiple part products.

Applicant - GE HEALTHCARE
The firm name holding legal responsibility for Visipaque 270. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020351
The FDA assigned number to Visipaque 270. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Visipaque 270. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Mar 22, 1996
The date Visipaque 270 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Visipaque 270. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Visipaque 270 is in. Format is RX, OTC, DISCN.

Applicant Full Name - Ge Healthcare
The full name of the firm holding legal responsibility for the new application of Visipaque 270.

Visipaque 270